Abstract
SLV306, a potent neutral endopeptidase (NEP) inhibitor with additional endothelin-converting enzyme (ECE)-inhibitory activity, in doses of 200, 400, and 800 mg reduced pulmonary and right atrial pressures, although there was not a clear dose response. Systemic blood pressure, heart rate, and cardiac output were unaffected. SLV306 increased plasma natriuretic peptides and big endothelin-1 levels in a dose-dependent manner, confirming NEP and ECE inhibition. The combined inhibition of NEP and ECE may be useful in heart failure by reducing right and left cardiac filling pressures.
Publication types
-
Clinical Trial
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Aspartic Acid Endopeptidases / antagonists & inhibitors*
-
Benzazepines / administration & dosage*
-
Blood Pressure / drug effects
-
Cardiac Output / drug effects
-
Endothelin-Converting Enzymes
-
Female
-
Heart Failure / physiopathology*
-
Heart Rate / drug effects
-
Humans
-
Male
-
Metalloendopeptidases
-
Middle Aged
-
Neprilysin / antagonists & inhibitors*
-
Pulmonary Artery / physiology*
-
Pulmonary Wedge Pressure / drug effects*
Substances
-
Benzazepines
-
SLV 306
-
Aspartic Acid Endopeptidases
-
Metalloendopeptidases
-
Neprilysin
-
Endothelin-Converting Enzymes